Zeltiq Announces Third Quarter 2015 Financial Results
34% Year-Over-Year Revenue Growth to $61.2 Million; Increases Full Year 2015 Revenue & Profitability Guidance; Receives FDA Clearance to Treat Submental Fat; Announces Collaboration With Massachusetts General Hospital for Treatment of Acne
/EINPresswire.com/ -- PLEASANTON, CA--(Marketwired - October 27, 2015) -
- 337 systems shipped, compared to 260 systems in third quarter 2014, bringing total system installed base to 4,247 systems
- 247,298 revenue cycles, up 55% from third quarter 2014
- Third quarter GAAP net income of $2.1 million, or $0.05 per share
- Third quarter Adjusted EBITDA of $5.6 million, or 9.2% of total revenue
ZELTIQ
Mark Foley, President and Chief Executive Officer, said, "I am very pleased with our ongoing, successful execution and our ability to continue to expand and grow the non-invasive fat reduction market which we believe remains in its early stages of evolution. Our third quarter revenue of $61.2M reflects the significant momentum we are experiencing, our expanding leadership position and our ability to continue to penetrate the largely untapped $4 billion non-invasive fat reduction market. In the quarter, over 50% of our revenue came from consumables and our 34% year-over-year total revenue growth was driven by our ninth consecutive quarter of year-over-year account utilization growth. These results and our expectations for the fourth quarter have led us to raise our full year revenue guidance to approximately $252 million."
Mr. Foley continued, "I am also pleased with the progress we continue to make on our strategic initiatives which include new product introductions, expanded indications, increasing brand awareness, shorter treatment times and increasing account utilization. In the third quarter we expanded our direct-to-consumer pilot, continued the successful roll out of our CoolSmooth PRO™ applicator, received FDA clearance to treat submental fat and launched our CoolMini applicator. Early feedback on our CoolMini applicator and its ability to treat submental fat has been very positive and we are excited about the significant new market opportunity CoolMini opens up and its ability to bring new patients into the aesthetic channel. Our CoolSmooth Pro applicator continues to receive positive feedback as more physicians experience the economic and convenience benefits of a shorter treatment time and better practice efficiency. In addition, we remain on track to introduce colder temperatures to our suction-based applicators in 2016 which we believe will enable our practices to reduce treatment times by almost half. Our direct-to-consumer pilot continues to generate positive results and our expansion into seven additional U.S. cities and one international market is having a measurable effect. Lastly, we are pleased to announce that we entered into a collaboration and license agreement with Massachusetts General Hospital (MGH) for the treatment of acne. The agreement provides ZELTIQ with the rights, on an exclusive worldwide basis, to the intellectual property generated from the collaboration. As part of this, we will be paying MGH a 3% royalty for any future products that are commercialized under this agreement. We have confidence that our technology, strategic initiatives, deep pipeline, marketing expertise and compelling practice economics will continue to drive robust top-line growth."
Third Quarter Financial Review
Total revenue for the third quarter 2015 was $61.2 million, consisting of $29.3 million of system revenue and $31.9 million of consumable revenue. This compares to total revenue of $45.7 million, consisting of $24.8 million of system revenue and $20.9 million of consumable revenue for the third quarter 2014. Total revenue cycles shipped increased 55% to 247,298 for the third quarter 2015, compared to 159,116 for the third quarter 2014.
Gross profit was $45.2 million, or 74% of revenue, for the third quarter 2015, compared to gross profit of $33.1 million, or 73% of revenue, for the third quarter 2014. Operating expenses for the third quarter 2015 were $43.2 million, compared to $28.2 million for the third quarter 2014.
Income from operations for the third quarter 2015 was $1.9 million, compared to $5.0 million for the third quarter 2014. Net income for the third quarter 2015 was $2.1 million, or $0.05 per share, compared to $4.8 million for the third quarter 2014, or $0.12 per share. Weighted average diluted shares outstanding was 40.9 million for the third quarter 2015 and 2014.
On a non-GAAP basis, the Company reported adjusted EBITDA of $5.6 million, or 9% of revenue, for the third quarter 2015, compared to $7.9 million, or 17% of revenue, for the third quarter 2014.
Cash and cash equivalents, short-term investments, and long-term investments were $50.5 million as of September 30, 2015 compared to $48.1 million as of September 30, 2014, and $53.1 million as of June 30, 2015.
Revised Full Year 2015 Financial Guidance
ZELTIQ is updating its previously stated financial guidance for the full year 2015, provided on its second quarter 2015 earnings conference call:
- Revenue guidance of approximately $252 million which includes approximately $3 million of currency headwinds; up from prior guidance of $245 million to $247 million
- Consumable revenue of approximately 50% of total revenue; unchanged from prior guidance
- Gross profit margin of approximately 71% of total revenue; unchanged from prior guidance
- Operating expenses of approximately 69% of total revenue; improved from prior guidance of 69% to 70%
- Stock-based compensation, depreciation, and amortization expense of approximately 7% of total revenue; unchanged from prior guidance
- Adjusted EBITDA margin of approximately 9% of total revenue; up from prior guidance of 8% to 9%
Additional information regarding ZELTIQ's results and guidance can be found in ZELTIQ's Supplemental Financial and Operational Information schedule by CLICKING HERE or by visiting the Investor Relations section of ZELTIQ's website at www.zeltiq.com.
Use of Non-GAAP Financial Measures
ZELTIQ has supplemented its GAAP net income (loss) with a non-GAAP measure of Adjusted EBITDA. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of ZELTIQ, facilitates a more meaningful comparison of results for current periods with previous operating results, and assists management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. A reconciliation of non-GAAP Adjusted EBITDA to GAAP net income (loss) in the most directly comparable GAAP measure is provided in the schedule below.
There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with ZELTIQ's consolidated financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measure provided in the schedule below.
Conference Call
ZELTIQ will hold a conference call on Tuesday, October 27, 2015 at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The dial-in numbers are (877) 280-7291 for domestic callers and (707) 287-9361 for international callers. The conference ID number is 55676149. A live webcast of the conference call will be available online from the investor relations page of the company's corporate website at www.coolsculpting.com.
A replay of the webcast will remain available on ZELTIQ's website, www.coolsculpting.com, until ZELTIQ releases its fourth quarter 2015 financial results. In addition, a telephonic replay of the call will be available until November 3, 2015. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay conference ID number 55676149.
About ZELTIQ® Aesthetics
ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting
Forward-Looking Statements
The statements made in this press release regarding ZELTIQ's estimate of the worldwide opportunity of $4B, its belief that CoolMini offers a sizable new market opportunity, its belief that it is on track to introduce colder temperatures to its suction-based applicators in 2016, its belief that such introduction will enable practices to reduce treatment times by almost half, its growth prospects and financial projections for the full year 2015, and its confidence in its recently stated long term financial objectives, are forward-looking statements. The words "believe," "expect," "will", and "guidance" and similar words that denote future events or results identify these forward-looking statements. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond ZELTIQ's control and that could materially affect ZELTIQ's actual business operations and financial performance and condition. Factors that could materially affect ZELTIQ's business operations and financial performance and condition include, but are not limited to: less than anticipated growth in the number of physicians electing to purchase CoolSculpting Systems; patient demand for CoolSculpting procedures may be lower than ZELTIQ expects; product or procedure announcements by competitors may decrease demand for CoolSculpting procedures; ZELTIQ may incorrectly estimate or control its future expenditures; ZELTIQ may incorrectly estimate the timing of new product development and new product launch; ZELTIQ's sales and marketing plans may fail to increase sales as ZELTIQ expects; individual patients may not experience the same results with CoolMini as the average patient in the clinical trials; as well as those other risks and uncertainties set forth in ZELTIQ's Quarterly Report on Form 10-Q for the second quarter ended June 30, 2015, filed with the SEC on July 30, 2015. These forward-looking statements speak only as of the date of this press release. ZELTIQ expressly disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events or otherwise.
ZELTIQ Aesthetics, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
September 30, December 31,
2015 2014
--------------- ---------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 35,618 $ 28,649
Short-term investments 11,235 16,286
Accounts receivable, net 32,908 21,472
Inventory 28,783 15,536
Prepaid expenses and other current assets 8,716 7,060
--------------- ---------------
Total current assets 117,260 89,003
Long-term investments 3,620 4,805
Restricted cash 459 560
Property and equipment, net 4,770 3,724
Intangible asset, net 5,255 5,780
Other assets 147 33
--------------- ---------------
Total assets $ 131,511 $ 103,905
=============== ===============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 12,159 $ 5,824
Accrued and other current liabilities 32,019 21,450
Deferred revenue 7,198 5,069
Current portion of capital lease
obligations 123 120
--------------- ---------------
Total current liabilities 51,499 32,463
Long-term deferred revenue 157 622
Long-term capital lease obligations, less
current portion 170 262
Other non-current liabilities 568 39
--------------- ---------------
Total liabilities $ 52,394 $ 33,386
--------------- ---------------
STOCKHOLDERS' EQUITY:
Total stockholders' equity 79,117 70,519
--------------- ---------------
Total liabilities and stockholders'
equity $ 131,511 $ 103,905
=============== ===============
ZELTIQ Aesthetics, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------- -------------------------
2015 2014 2015 2014
------------ ------------ ------------ ------------
Revenue $ 61,202 $ 45,670 $ 177,191 $ 123,706
Cost of revenue 16,041 12,555 48,535 35,231
------------ ------------ ------------ ------------
Gross profit 45,161 33,115 128,656 88,475
------------ ------------ ------------ ------------
Operating expenses:
Research and
development 5,464 4,241 17,352 12,861
Sales and marketing 30,647 19,014 87,253 60,253
General and
administrative 7,115 4,896 22,156 14,843
------------ ------------ ------------ ------------
Total operating
expenses 43,226 28,151 126,761 87,957
------------ ------------ ------------ ------------
Income from operations 1,935 4,964 1,895 518
Interest income, net 13 14 40 47
Other income (expense),
net 359 (189) (508) (338)
------------ ------------ ------------ ------------
Income before income
taxes 2,307 4,789 1,427 227
Provision for income
taxes 160 7 231 13
------------ ------------ ------------ ------------
Net income 2,147 4,782 1,196 214
============ ============ ============ ============
Net income per share,
basic $ 0.06 $ 0.13 $ 0.03 $ 0.01
============ ============ ============ ============
Weighted average shares
of common stock
outstanding used in
computing net income
per share, basic 38,881,183 37,630,222 38,640,269 37,430,337
============ ============ ============ ============
Net income per share,
diluted $ 0.05 $ 0.12 $ 0.03 $ 0.01
============ ============ ============ ============
Weighted average shares
of common stock
outstanding used in
computing net income
per share, diluted 40,860,593 40,926,034 40,724,261 40,781,141
============ ============ ============ ============
ZELTIQ Aesthetics, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
Nine Months Ended
September 30,
-------------------------------
2015 2014
--------------- ---------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 1,196 $ 214
Adjustments to reconcile net income to net
cash provided by (used in) operating
activities:
Depreciation and amortization 1,712 1,350
Stock-based compensation 10,261 7,029
Deferred income taxes - 37
Amortization of investment premium, net 63 183
Provision for doubtful accounts
receivable 270 134
Provision for excess and obsolete
inventory 403 688
Loss on disposal and write-off of
property and equipment - 17
Changes in operating assets and
liabilities:
Accounts receivable (11,773) (5,653)
Inventory (13,698) (9,684)
Prepaid expenses and other assets (1,794) 177
Deferred revenue, net of deferred
costs 1,681 2,426
Accounts payable, accrued and other
liabilities 17,573 (2,076)
--------------- ---------------
Net cash provided by (used in)
operating activities 5,894 (5,158)
--------------- ---------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investments (12,079) (9,011)
Proceeds from sale of investments - 1,000
Proceeds from maturity of investments 18,260 14,968
Purchase of property and equipment (2,332) (1,216)
Change in restricted cash 94 (252)
--------------- ---------------
Net cash provided by investing
activities 3,943 5,489
--------------- ---------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on capital leases (89) -
Proceeds from issuance of common stock
upon exercise of stock options and from
employee stock purchase plan 4,136 2,714
Tax payments related to shares withheld
for vested restricted stock units (6,577) (3,774)
Tax effect of employee stock plans 26 27
--------------- ---------------
Net cash used in financing activities (2,504) (1,033)
--------------- ---------------
Effect of exchange rate changes on cash and
cash equivalents (364) (155)
--------------- ---------------
NET INCREASE (DECREASE) IN CASH AND CASH
EQUIVALENTS 6,969 (857)
CASH AND CASH EQUIVALENTS-Beginning of
period 28,649 25,798
--------------- ---------------
CASH AND CASH EQUIVALENTS-End of period $ 35,618 $ 24,941
=============== ===============
ZELTIQ Aesthetics, Inc.
Reconciliation of Net Income to Adjusted Earnings Before Interest, Taxes,
Depreciation,
Amortization and Stock-Based Compensation (Adjusted EBITDA)
(In thousands, except for percentages)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------- ---------------------
Dollars 2015 2014 2015 2014
---------- ---------- ---------- ----------
Net income, as reported $ 2,147 $ 4,782 $ 1,196 $ 214
Adjustments to net income:
Interest income, net and
other income (expense), net (372) 175 468 291
Provision for income taxes 160 7 231 13
Depreciation and
amortization 650 417 1,712 1,350
Stock-based compensation
expense 3,028 2,518 10,261 7,029
---------- ---------- ---------- ----------
Total adjustments to net
income 3,466 3,117 12,672 8,683
Adjusted EBITDA $ 5,613 $ 7,899 $ 13,868 $ 8,897
========== ========== ========== ==========
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------- ---------------------
As a Percentage of Revenue 2015 2014 2015 2014
---------- ---------- ---------- ----------
Net income, as reported 3.5% 10.5% 0.7% 0.2%
Adjustments to net income:
Interest income, net and
other income (expense), net -0.6% 0.4% 0.2% 0.2%
Provision for income taxes 0.3% 0.0% 0.1% 0.0%
Depreciation and
amortization 1.1% 0.9% 1.0% 1.1%
Stock-based compensation
expense 4.9% 5.5% 5.8% 5.7%
---------- ---------- ---------- ----------
Total adjustments to net
income 5.7% 6.8% 7.1% 7.0%
Adjusted EBITDA Margin 9.2% 17.3% 7.8% 7.2%
========== ========== ========== ==========
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
